Asker Healthcare Group AB
Sweden · SE0024171458 · reports in SEK · Europe
The answers
From the annual report for the year to Dec 31, 2025. Each line says what it is based on.
- Is it growing?Good
- Revenue +12% in the year to Dec 31, 2025, on the year before.
- Is it a good business?Fair
- It earned 7.5% on its shareholders' equity in the year to Dec 31, 2025.
- Is it safe?Fair
- Equity is 39% of its assets, and operations brought in cash in the year.
- Is the price fair?n/a
- Not answered: no exchange publishes this company's price for free reuse, so there is no P/E here.
The year
Year to Dec 31, 2025, consolidated, in SEK.
revenue
operating margin
net profit
Year by year
As filed; an earlier year can differ from its own report when the company restated it.
| Dec 2024 | Dec 2025 | |
|---|---|---|
| Revenue | SEK 15.0B | SEK 16.8B |
| Operating profit | SEK 966M | SEK 1.0B |
| Net profit to shareholders | SEK 360M | SEK 492M |
| Earnings per share | SEK 0.74 | SEK 1.25 |
| Cash from operations | SEK 1.2B | SEK 1.3B |
| Cash | SEK 490M | SEK 884M |
| Total assets | SEK 13.1B | SEK 16.8B |
| Equity | SEK 3.5B | SEK 6.6B |
What they do
In the company's own words, from the annual report.
Asker Healthcare Group är en partner till vårdgivare i Europa, och tillhandahåller medicinskt förbrukningsmaterial och medicinteknisk utrustning. Koncernen utvecklar och förvärvar ledande företag som bidrar positivt till de europeiska hälso- och sjukvårdssystemen. Verksamheten bedrivs i 19 länder. Koncernen är organiserad i tre affärsområden
Source: the company’s annual financial report in ESEF, via filings.xbrl.org (XBRL International). Listed shares from ESMA’s FIRDS register; ESMA does not endorse this site. Ryufin computed the answers and ratios from the filed figures.